“Flight NZ29 is ready to board at Gate 4…” I’m in transit in Houston Airport, returning from my first in-person attendance in four years at the Association for Research in Vision and Ophthalmology conference (ARVO). As I mentally prepare for the 14.5 hours aboard my waka rererangi, I reflect on what
The 2023 five-day Association for Research in Vision and Ophthalmology (ARVO) conference was held in New Orleans, bringing many ophthalmic researchers from across the world face-to-face for the first time since the Covid pandemic. The following is a selection of just a few of the studies and breakth
New Zealand’s healthcare providers are over-prescribing opioids to patients post-surgery, potentially fuelling addiction, a new study has found.
Kāpō Māori Aotearoa (KMA) has released a Māori referral pathway to improve access to its Specialist Kāpō Māori Service (SKMS).
The Cornea and Contact Lens Society (CCLS) is hosting a webinar on the impact of cosmetics on the ocular surface on Wednesday 7 June at 7.30pm NZ standard time. Founders of UK-based award-winning
British keyboardist for 1970s rockers Yes and David Bowie, Rick Wakeman recently admitted his many health woes now include macular generation in his left eye.
The Lighthouse Vision Trust has farewelled occupational therapist Gail Hughes and optometrist John Veale, who tirelessly served the Christchurch low vision community at Burwood Hospital’s Low Vision Clinic for 15 and 30-plus years, respectively.
Astellas Pharma has acquired Iveric Bio for US$5.9bn, to further its goal of becoming a world-class ophthalmology entity with a focus on blindness and regeneration, said Astellas in a statement. The
A study of Allergan’s Xen45 minimally invasive glaucoma surgery (MIGS) implant concluded it was safe and effective in primary open angle glaucoma (POAG) eyes with high myopia. The multicentre Italian
Addressing the rapidly-evolving importance of biometry in myopia management, the Centre for Ocular Research & Education (CORE) has dedicated Issue 71 of Contact Lens Update to the topic.
Visus Therapeutics announced Brimochol PF, its preservative-free ophthalmic solution for the treatment of presbyopia, met its primary and secondary endpoints in the phase 3 BRIO-I clinical
Early on in secondary school, my English teacher announced to the class that he’d decided which movie we were going to study that year. With bated breath he revealed it would be The Matrix and the room of boys collectively exhaled.
